Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneron Pharmaceuticals and Sanofi are conducting a clinical study titled ‘A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis.' This study aims to evaluate the pharmacokinetics and safety of Dupilumab, a drug administered subcutaneously, in young patients suffering from Prurigo Nodularis. The significance of this study lies in its potential to expand treatment options for this age group.
The intervention being tested is Dupilumab, an experimental drug administered via subcutaneous injection. It is designed to treat Prurigo Nodularis by targeting specific pathways involved in the disease’s development.
The study is interventional, with a single-group assignment and no masking, focusing on treatment as its primary purpose. Participants will undergo a 42 to 44-week process, including screening, treatment, and follow-up periods, with a total of six planned visits.
The study started on May 15, 2024, with a primary completion date yet to be announced. The latest update was submitted on June 25, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This update could positively impact Regeneron and Sanofi’s stock performance by enhancing investor confidence in their pipeline’s potential. The study’s success could also position these companies favorably against competitors in the dermatological treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.